Experienced in Ascites

Gabriel Lindahl

Linkoeping, E, SE 
Experienced in Ascites
Linkoeping, E, SE 
OverviewLocationsClinical Research

Overview

Gabriel Lindahl practices in Linkoeping, Sweden. Mr. Lindahl is rated as an Experienced expert by MediFind in the treatment of Ascites. His top areas of expertise are Ovarian Cancer, Milroy Disease, Endometrial Cancer, Salpingo-Oophorectomy, and Lymphadenectomy.

His clinical research consists of co-authoring 23 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Ascites.

Gender
Male

Locations

Linkoeping, E, Sweden
Other Locations
Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drugs: Bevacizumab, Atezolizumab, Chemotherapy
Study Phase: Phase 3
View 1 Less Clinical Trial

23 Total Publications

ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Journal: Gynecologic oncology
Published: January 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lindahl's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile